Roche licenses neurodegenerative programmes
This article was originally published in Scrip
Executive Summary
Roche has licensed two preclinical programmes focused on therapeutics to slow down neurodegenerative disorders from reMYND, a small Belgian biotechnology company. The deal that could be worth more than €500 million to reMYND in milestone and other payments, including an undisclosed upfront payment, plus royalties on any resulting product sales.